Suscribirse

SARS-CoV-2 infection of thymus induces loss of function that correlates with disease severity - 05/04/23

Doi : 10.1016/j.jaci.2023.01.022 
Marco Rosichini, MSc a, b, , Veronica Bordoni, PhD a, c, , Domenico Alessandro Silvestris, PhD a, Davide Mariotti, MSc c, Giulia Matusali, PhD d, Antonella Cardinale, MSc a, Giovanna Zambruno, MD e, Angelo Giuseppe Condorelli, PhD e, Sara Flamini, PhD a, Shirley Genah, PhD a, Marialuigia Catanoso, MD a, f, Franca Del Nonno, MD g, Matteo Trezzi, MD h, Lorenzo Galletti, MD h, Cristiano De Stefanis, MSc i, Nicolò Cicolani, BSc j, Stefania Petrini, PhD j, Concetta Quintarelli, PhD a, k, Chiara Agrati, PhD a, c, , Franco Locatelli, MD a, l, , Enrico Velardi, PhD a,
a Department of Pediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy 
e Genodermatosis Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy 
h Cardiac Surgery Unit, Department of Pediatric Cardiology and Cardiac Surgery, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy 
i Pathology Unit, Core Research Laboratories, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy 
j Confocal Microscopy Core Facility, Research Center, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy 
b Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy 
c Cellular Immunology Laboratory, INMI L Spallanzani – IRCCS, Rome, Italy 
d Virology Laboratory, INMI L Spallanzani – IRCCS, Rome, Italy 
g Pathology Unit, INMI L Spallanzani – IRCCS, Rome, Italy 
f Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy 
k Department of Clinical Medicine and Surgery, University of Naples Federico II, Rome, Italy 
l Catholic University of the Sacred Heart, Rome, Italy 

Corresponding author: Enrico Velardi, PhD, Department of Pediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children’s Hospital, IRCCS, Rome, 00146, Italy.Department of Pediatric Hematology and OncologyCell and Gene TherapyBambino Gesù Children’s HospitalIRCCSRome00146Italy

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

Lymphopenia, particularly when restricted to the T-cell compartment, has been described as one of the major clinical hallmarks in patients with coronavirus disease 2019 (COVID-19) and proposed as an indicator of disease severity. Although several mechanisms fostering COVID-19–related lymphopenia have been described, including cell apoptosis and tissue homing, the underlying causes of the decline in T-cell count and function are still not completely understood.

Objective

Given that viral infections can directly target thymic microenvironment and impair the process of T-cell generation, we sought to investigate the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on thymic function.

Methods

We performed molecular quantification of T-cell receptor excision circles and κ-deleting recombination excision circles to assess, respectively, T- and B-cell neogenesis in SARS-CoV-2–infected patients. We developed a system for in vitro culture of primary human thymic epithelial cells (TECs) to mechanistically investigate the impact of SARS-CoV-2 on TEC function.

Results

We showed that patients with COVID-19 had reduced thymic function that was inversely associated with the severity of the disease. We found that angiotensin-converting enzyme 2, through which SARS-CoV-2 enters the host cells, was expressed by thymic epithelium, and in particular by medullary TECs. We also demonstrated that SARS-CoV-2 can target TECs and downregulate critical genes and pathways associated with epithelial cell adhesion and survival.

Conclusions

Our data demonstrate that the human thymus is a target of SARS-CoV-2 and thymic function is altered following infection. These findings expand our current knowledge of the effects of SARS-CoV-2 infection on T-cell homeostasis and suggest that monitoring thymic activity may be a useful marker to predict disease severity and progression.

El texto completo de este artículo está disponible en PDF.

Graphical abstract




El texto completo de este artículo está disponible en PDF.

Key words : COVID-19, SARS-CoV-2, immunodeficiency, thymus, T cells, thymic epithelial cells

Abbreviations used : ACE2, βTREC, cjKREC, CK1, CK5, COVID-19, cTEC, DEGs, EpCAM, hTEC, ICU, KREC, LCMV, mTEC, sjKREC, sjTREC, TEC, SARS-CoV-2, TREC, UEA1


Esquema


 E.V. was supported by grants from the Amy Stelzer Manasevit Research Program, the Italian Association for Cancer Research (AIRC), and the Italian Ministry of Health (“Ricerca Corrente”). F.L. was supported by grants from AIRC (Special Program Metastatic disease: The Key Unmet Need in Oncology 5 per mille 2018 Project Code 21147 and Accelerator Award 2017 INCAR), Ministero dell’Istruzione dell’Università e della Ricerca (grant PRIN ID 2017 WC8499_004), and the Italian Ministry of Health (grant RF-2016-02364388). S.F and S.G. were supported by the AIRC fellowship for Italy. The study was also supported by the European Virus Archive - GLOBAL funded by European Union's Horizon 2020 research and innovation programme (grant agreement no. 871029).
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2023  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 151 - N° 4

P. 911-921 - avril 2023 Regresar al número
Artículo precedente Artículo precedente
  • 2022: The year in review
  • Zuhair K. Ballas
| Artículo siguiente Artículo siguiente
  • Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
  • Kai M.T. Sauerwein, Christoph B. Geier, Roman F. Stemberger, Raphael Rossmanith, Hüseyin Akyaman, Peter Illes, Michael B. Fischer, Martha M. Eibl, Jolan E. Walter, Hermann M. Wolf

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.